Get notified when KALA files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsRed Flags Detected
- Going Concern (new) — Management has substantial doubt about the company's ability to continue as a going concern due to insufficient resources to fund operations for the next twelve months.
- Obligated to Pay 25% of All Proceeds (new) — A quarter of any financing proceeds must immediately go to loan repayment, reducing net cash available to the company.
- Obligated to Pay Ten Percent of the Proceeds (new) — An additional 10% of equity proceeds is owed to Oxford, further diluting the net benefit of this offering.
KALA BIO launches at-the-market offering of up to $15M common stock at $0.62/share
Filed January 8, 2026 · ~2 min read
Key Changes
-
high
KALA BIO is offering up to $15 million of common stock in an at-the-market offering, with shares sold at prevailing market prices.
The Offering verify on EDGAR → -
medium
The company will not receive any proceeds from sales by selling stockholders, if any; all proceeds from primary shares go to the company.
Use of Proceeds verify on EDGAR → -
high
25% of all financing proceeds must be used to repay a loan, and 10% of equity proceeds (up to $1M) must be paid to Oxford, reducing net cash available.
Use of Proceeds verify on EDGAR →
3 more material changes behind this preview — plus the full narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (ORCL 10-Q) is open in full — no account needed.
Partner
Trade KALA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Figures/quotes linked to EDGAR · Narrative written by AI · Sep 2, 2026 · How we verify